Literature DB >> 10412802

A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy.

M B Delisle1, J R Murrell, R Richardson, J A Trofatter, O Rascol, X Soulages, M Mohr, P Calvas, B Ghetti.   

Abstract

Recently intronic and exonic mutations in the Tau gene have been found to be associated with familial neurodegenerative syndromes characterized not only by a predominantly frontotemporal dementia but also by the presence of neurological signs consistent with the dysfunction of multiple subcortical neuronal circuitries. Among families, the symptomatology appears to vary in quality and severity in relation to the specific Tau gene mutation and often may include parkinsonism, supranuclear palsies, and/or myoclonus, in addition to dementia. We carried out molecular genetic and neuropathological studies on two patients from a French family presenting, early in their fifth decade, a cognitive impairment and supranuclear palsy followed by an akinetic rigid syndrome and dementia. The proband died severely demented 7 years after the onset of the symptoms; currently, his brother is still alive although his disease is progressing. In both patients, we found a Tau gene mutation in exon 10 at codon 279, resulting in an asparagine to lysine substitution (N279K). Neuropathologically, widespread neuronal and glial tau accumulation in the cortex, basal ganglia, brain stem nuclei as well as in the white matter were the hallmark of the disease. These deposits were shown by immunohistochemistry and immunoelectron microscopy, using a battery of antibodies to phosphorylation-dependent and phosphorylation-independent epitopes present in multiple tau regions. In the neocortex, tau-immunopositive glial cells were more numerous than immunopositive neurons; the deeper cortical layers as well as the white matter adjacent to the cortex contained the largest amount of immunolabeled glial cells. In contrast, some brain stem nuclei contained more neurons with tau deposits than immunolabeled glial cells. The correlation of clinical, neuropathological and molecular genetic findings emphasize the phenotypic heterogeneity of diseases caused by Tau gene mutations. Furthermore, to test the effect of the N279K mutation and compare it with the effect of the P301L exon 10 mutation on alternative splicing of Tau exon 10, we used an exon amplification assay. Our results suggest that the N279K mutation affects splicing similar to the intronic mutations, allowing exon 10 to be incorporated more frequently in the Tau transcript.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412802     DOI: 10.1007/s004010051052

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  27 in total

Review 1.  Frontotemporal dementia and tauopathy.

Authors:  Y Yoshiyama; V M Lee; J Q Trojanowski
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

2.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Authors:  Maiko Ono; Naruhiko Sahara; Katsushi Kumata; Bin Ji; Ruiqing Ni; Shunsuke Koga; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Mari Yoshida; Isao Hozumi; Yasumasa Yoshiyama; John C van Swieten; Agneta Nordberg; Tetsuya Suhara; Ming-Rong Zhang; Makoto Higuchi
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

Review 3.  Protein astrogliopathies in human neurodegenerative diseases and aging.

Authors:  Gabor G Kovacs; Virginia M Lee; John Q Trojanowski
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

4.  Potential neuroprotective strategies against tauopathy.

Authors:  Jeanna M Wheeler; Chris R Guthrie; Brian C Kraemer
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

5.  The C-terminus of tau protein plays an important role in its stability and toxicity.

Authors:  Junhua Geng; Lu Xia; Wanjie Li; Fei Dou
Journal:  J Mol Neurosci       Date:  2014-05-02       Impact factor: 3.444

Review 6.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

7.  Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome.

Authors:  Jonathan D Rohrer; Dominic Paviour; Jana Vandrovcova; John Hodges; Rohan de Silva; Martin N Rossor
Journal:  Neurodegener Dis       Date:  2010-09-14       Impact factor: 2.977

Review 8.  The cytoskeleton in neurodegenerative diseases.

Authors:  Nigel J Cairns; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Pathol       Date:  2004-11       Impact factor: 7.996

9.  The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family.

Authors:  Salvatore Spina; Martin R Farlow; Frederick W Unverzagt; David A Kareken; Jill R Murrell; Graham Fraser; Francine Epperson; R Anthony Crowther; Maria G Spillantini; Michel Goedert; Bernardino Ghetti
Journal:  Brain       Date:  2007-12-07       Impact factor: 13.501

10.  No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration.

Authors:  Lena Skoglund; Sofie Ingvast; Toshifumi Matsui; Stefanie H Freeman; Matthew P Frosch; Rosemarie Brundin; Vilmantas Giedraitis; John H Growdon; Bradley T Hyman; Lars Lannfelt; Martin Ingelsson; Anna Glaser
Journal:  Dement Geriatr Cogn Disord       Date:  2009-11-23       Impact factor: 2.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.